Preclinical News and Research

RSS

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

Conformetrix's NMR-based technology to be applied across AstraZeneca's pre-clinical therapeutic pipeline

Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

16 Apr 2012

New compound reverses major symptoms associated with FXS

A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.

12 Apr 2012

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart- drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

11 Apr 2012

Botanical formula controls aggressive human prostate tumors in mice

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells.

11 Apr 2012

UofL wins NIH grant for cardiac clinical research center

During his 18-year tenure at UofL, Dr. Roberto Bolli has generated more than $100 million in grants for basic research from the NIH. Today, Bolli joined with University of Louisville President James R. Ramsey to announce a new NIH grant he has won for clinical research, a seven-year, $3.4 million grant from the National Heart, Lung and Blood Institute to establish one of seven regional centers across the United States in the Cardiac Cell Therapy Research Network.

10 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent application

Sunshine Biopharma Inc. is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications.

9 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

NINDS awards NeuroSigma Phase I grant to develop TFN-covered stents

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has been awarded a Phase I NIH-STTR grant from the National Institute of Neurological Disorders and Stroke (NINDS) for the further development of its Thin-Film Nitinol (TFN)-covered stent for the potential treatment of brain aneurysms.

9 Apr 2012

Inflammasome involved in regulating Age-Related Macular Degeneration

Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration.

9 Apr 2012

Presage Biosciences enters cancer research agreement with Millennium

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.

7 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

Vaccination most promising against asthma

Asthma is a chronic inflammatory and respiratory disease caused by an abnormal reactivity to allergens in the environment. Of the several avenues of exploration that are currently being developed, vaccination appears to be the most promising approach.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

Study assesses link between antifolate medications, KRAS mutations and amplification

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

5 Apr 2012

New cell and animal model of IBC

Inflammatory breast cancer (IBC) is a very aggressive, often misunderstood type of cancer that is diagnosed more frequently in younger women compared with other types of breast cancer. The five-year survival rate is between 25 and 50 percent-significantly lower than the survival rate for other types of breast cancer. The reason for the poor prognosis is that IBC usually grows rapidly and often spreads quickly to other parts of the body, including the brain, bone and lymph nodes.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Preclinical News and Research

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Conformetrix's NMR-based technology to be applied across AstraZeneca's pre-clinical therapeutic pipeline

New compound reverses major symptoms associated with FXS

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

Botanical formula controls aggressive human prostate tumors in mice

UofL wins NIH grant for cardiac clinical research center

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent application

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

NINDS awards NeuroSigma Phase I grant to develop TFN-covered stents

Inflammasome involved in regulating Age-Related Macular Degeneration

Presage Biosciences enters cancer research agreement with Millennium

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Vaccination most promising against asthma

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Study assesses link between antifolate medications, KRAS mutations and amplification

New cell and animal model of IBC

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics